Madrigal pharmaceuticals secures $500 million in senior secured credit from blue owl managed funds to further extend leadership position in mash

Conshohocken, pa., july 22, 2025 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq: mdgl), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (mash), today announced that it has entered into a $500 million senior secured credit facility with funds managed by blue owl capital (nyse: owl), a leading alternative asset manager, to primarily advance madrigal's pipeline to further extend its leadership position in mash.
MDGL Ratings Summary
MDGL Quant Ranking